A 68-year-old man was admitted for bleeding tendency and generalized lymphadenopathy. A diagnosis of idiopathic thrombocytopenic purpura (ITP) associated with mantle cell lymphoma was made. The anti-CD20 monoclonal antibody rituximab 375mg/m
2 was given intravenously once weekly for four consecutive weeks. The patient's platelet counts increased gradually from 0.6×10
4/μ
l to 5.8×10
4/μ
l. At eighteen weeks after discontinuation of rituximab medication, his platelet count increased again to 10.3×10
4/μ
l and this value has been sustained up to the time of writing. This suggests that rituximab is useful in the treatment of ITP associated with malignant lymphoma.
抄録全体を表示